Brief: CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
23/06/2025 13:25
June 23 (Reuters) - CERo Therapeutics Holdings Inc CERO.O: CERO THERAPEUTICS HOLDINGS, INC. ANNOUNCES FIRST PATIENT COMPLETES DOSE-LIMITING TOXICITY OBSERVATION PERIOD WITH NO REPORTED DLTS IN PHASE 1 TRIAL OF CER-1236 Source text: ID:nGNXzhY1Z Further company coverage: CERO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CERo Therapeutics Holdings
See all newsBrief: Cero Therapeutics Hearing Review Council Issued Decision
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Brief: Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List